Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H19N.H3O4P |
Molecular Weight | 227.2383 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CC(C)CCCC(C)N
InChI
InChIKey=UGKNTPUWARSSNM-UHFFFAOYSA-N
InChI=1S/C8H19N.H3O4P/c1-7(2)5-4-6-8(3)9;1-5(2,3)4/h7-8H,4-6,9H2,1-3H3;(H3,1,2,3,4)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/29115866Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6891293 | https://www.ncbi.nlm.nih.gov/pubmed/14881080
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29115866
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6891293 | https://www.ncbi.nlm.nih.gov/pubmed/14881080
Octodrine is a stimulant that is structurally similar to amphetamine and is included in several so-called “pre-workout” and “fat-burning” supplements. Octodrine, has a history of use as a pharmaceutical drug. It was originally developed in the United States as an aerosolized treatment for bronchitis, laryngitis and other conditions Initially approved by the FDA in 1946 as Eskay’s Oralator, this inhaler appeared only in the 1949 edition of the Physicians’ Desk Reference. Octodrine was combined with several other medications, including theophylline, 3-octopamine, and adenosine, in multi-ingredient tablets sold between the early 1960s through the mid-2000s under the trade names Ambredin, Ordinal, Ordinal Retard and Ordinal Forte. Some proponents say octodrine is a safer alternative to other stimulants like ephedra and Dimethylamylamine (DMAA), but there is no scientific information to support this claim. Originally developed in the early 1950’s as a remedy to nasal congestion and as a possible anti-tumor drug, Octodrine has resurfaced as a key ingredient in dietary supplements for its stimulant and thermogenic benefits.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6891293 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Separation and conductimetric detection of C1-C7 aliphatic monocarboxylic acids and C1-C7 aliphatic monoamines on unfunctionized polymethacrylate resin columns. | 2004 Jun 11 |
|
On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors. | 2009 Nov 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29115866
Maximum daily intake 8.5 g
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
139033069
Created by
admin on Sat Dec 16 04:54:25 GMT 2023 , Edited by admin on Sat Dec 16 04:54:25 GMT 2023
|
PRIMARY | |||
|
I254D74U8J
Created by
admin on Sat Dec 16 04:54:25 GMT 2023 , Edited by admin on Sat Dec 16 04:54:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD